Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. held its 2024 annual performance briefing on May 21, 2025, to discuss financial status, development strategy, and corporate governance with investors [1] Group 1: Industry Performance - In 2024, the pharmaceutical manufacturing industry achieved a total revenue of 25,298.5 billion yuan, with a year-on-year change of 0.0% [2] - The industry's total operating costs were 14,729.6 billion yuan, reflecting a year-on-year increase of 2.0% [2] - The total profit for the industry was 3,420.7 billion yuan, showing a year-on-year decline of 1.1% [2] Group 2: Company Financials - The company reported an annual revenue of 2.16 billion yuan, with an operating profit of 131 million yuan and a net profit attributable to shareholders of 84 million yuan [2] - In Q1 2025, the net profit attributable to shareholders was approximately 23.06 million yuan [2] Group 3: Reasons for Profit Decline - The decline in net profit for 2024 was primarily due to a significant increase in R&D investment, reduced investment income, and rising operating expenses influenced by changes in medical insurance policies and market demand [2][4] Group 4: Future Growth Points - The company plans to enhance new drug research and technological innovation, with R&D investment reaching 277 million yuan in 2024, a year-on-year increase of 95.93% [2] - The company has made breakthroughs in innovative R&D, including the advancement of a new drug LH-1801 into phase III clinical trials and the approval of multiple generic drug production licenses [2][4] Group 5: Market and Investor Relations - The company emphasizes value management and investor relations, maintaining a consistent annual dividend payout ratio of 30% [5] - The company is committed to improving its image and enhancing communication with investors through various initiatives [5] Group 6: Regulatory Issues - The company is addressing a recent antitrust penalty by implementing corrective measures and has submitted an application for an administrative penalty hearing [4][5]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Viewpoints - The company has entered into a licensing agreement with Pfizer for its innovative PD-1/VEGF bispecific antibody SSGJ-707, which is expected to enhance its global presence and financial returns [1][2] - SSGJ-707 has shown promising clinical results, achieving excellent overall response rates (ORR) and disease control rates (DCR) in non-small cell lung cancer (NSCLC) patients, indicating its potential as a best-in-class treatment [2] - The company is expected to see significant revenue growth, with projected revenues of 10.23 billion RMB in 2025, reflecting a year-on-year growth rate of 12.3% [4] Financial Projections - The company’s net profit is projected to reach 2.36 billion RMB in 2025, with a growth rate of 13.0% [4] - The earnings per share (EPS) is expected to increase from 0.65 RMB in 2023 to 0.98 RMB in 2025 [4] - The company’s revenue is forecasted to grow from 7.82 billion RMB in 2023 to 12.65 billion RMB by 2027, with a compound annual growth rate (CAGR) of approximately 10.6% [4] Product Pipeline and Market Strategy - The company is focusing on expanding its product pipeline, with SSGJ-707 being a key driver for growth, alongside other mature products that are expected to continue generating revenue [3] - The company has established a global strategy, with products being sold in 16 countries and ongoing collaborations to expand its PD-1 pipeline [3]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Viewpoints - The company has entered into a licensing agreement with Pfizer for its innovative PD-1/VEGF bispecific antibody SSGJ-707, which is expected to enhance its global presence and financial returns [1][2] - SSGJ-707 has shown promising clinical results, achieving excellent overall response rates (ORR) and disease control rates (DCR) in non-small cell lung cancer (NSCLC) patients, indicating its potential as a best-in-class treatment [2] - The company is expected to see significant revenue growth driven by its core products and innovative pipeline, with projected net profits increasing from 2.36 billion RMB in 2025 to 2.98 billion RMB in 2027 [3][4] Financial Projections - The company’s revenue is projected to grow from 7.82 billion RMB in 2023 to 12.65 billion RMB in 2027, with year-over-year growth rates of 13.9% in 2023 and declining to 10.6% by 2027 [4] - The net profit is expected to increase from 1.55 billion RMB in 2023 to 2.98 billion RMB in 2027, with a notable recovery in 2024 at a growth rate of 34.9% [4] - The earnings per share (EPS) is projected to rise from 0.65 RMB in 2023 to 1.24 RMB in 2027 [4] Product and Market Strategy - The company is focusing on expanding its product offerings and market reach, with SSGJ-707 being a key component of its strategy to enhance its competitive position in the oncology market [2][3] - The company has established a global strategy, with products being sold in 16 countries and collaborations with international partners to expand its pipeline [3]

Financial Data and Key Metrics Changes - Sales for Q1 2025 were $1,767 million, up 2% year over year and up 10% quarter over quarter [6] - Consolidated adjusted EBITDA was $359 million, with specialties driven EBITDA of $262 million, up 7% year over year and 4% quarter over quarter [7] - Specialties driven EBITDA margin improved by approximately 70 basis points to 19% compared to the first quarter of last year [7] Business Line Data and Key Metrics Changes - Industrial Products sales were $344 million, up 3% year over year, with EBITDA of $76 million, up 6% [9] - Potash division reported sales of $405 million and EBITDA of $118 million, with average potash price at $300 CIF per ton, down year over year but up $15 per ton from the previous quarter [11] - Phosphate Solutions division had sales of $573 million, up 3%, and EBITDA of $139 million, with an EBITDA margin of 24% [13] - Growing Solutions division sales were $495 million, up 3% year over year, with EBITDA of $47 million, an increase of 12% [16] Market Data and Key Metrics Changes - Inflation rates were stable in the U.S. and EU, while Brazil saw a 30 basis point increase; China experienced a slight negative inflation of 0.1% year over year [20] - Grain price index increased slightly, with corn, wheat, and soybean prices improving; corn saw the largest quarterly gain [23] - Potash prices increased approximately 9% sequentially, while phosphate prices grew by about 4% [24] Company Strategy and Development Direction - The company aims to drive growth in specialty businesses to differentiate from commodity-based peers and maximize potash sales volumes [34] - Innovation remains a key focus, with plans to develop new products and solutions for existing and new clients [36] - The acquisition strategy continues, with recent acquisitions enhancing regional market presence and local production capabilities [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving market prices and stable supply, but cautioned about the impact of fulfilling lower-priced contracts with China and India [49] - The company maintains its 2025 guidance, expecting EBITDA for specialties driven divisions to be between $950 million to $1,150 million [32] - There is an expectation for higher potash prices, but the company has not made guidance concessions for potential tariffs [33] Other Important Information - The company ended the quarter with available resources of approximately $1,500 million and a net debt to adjusted EBITDA ratio of 1.2 times [31] - A recent management change in the Phosphate Solutions division aims to maintain market share and target geographic expansion [15] Q&A Session Summary Question: Insights on potash trade flows and pricing impact - Management noted that Eurasian players have been inconsistent in their production claims, making it difficult to predict market tightness and pricing impacts [48] Question: More details on the mix shift in Brazil and growing solutions - Brazil's B2B and B2C businesses are performing well, with strong specialty growth attributed to previous acquisitions [52]

Core Viewpoint - Sichuan Zimuongong Pharmaceutical Co., Ltd. is focusing on innovation and market expansion while enhancing production capacity and management efficiency to drive future growth [2][3]. Group 1: Company Overview - Zimuongong has a history of 245 years and specializes in drug research, production, and marketing, holding 26 invention patents and 99 drug production approvals across various forms [2]. - The company is primarily focused on the development of drugs for the nervous system and digestive system, with future emphasis on endocrine and analgesic drugs [2]. Group 2: Financial Performance - In 2024, Zimuongong achieved a revenue of 416 million yuan, a year-on-year increase of 1.87%, and a net profit attributable to shareholders of 85.64 million yuan [3]. - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 29.31 million yuan, with the total cash dividends over the last three years amounting to about 144 million yuan, representing 149.21% of the average annual net profit [4]. Group 3: Research and Development - Zimuongong increased its R&D investment by 81.18% compared to the same period in 2023, focusing on both innovative and generic drugs [3]. - The company is advancing its innovative drug pipeline, including the initiation of clinical trials for the Ma Jia Zi capsule and the successful launch of the Phosphate Oseltamivir capsule [3]. Group 4: Future Strategy - The company aims to adhere to its core business in pharmaceutical manufacturing while driving growth through innovation and marketing, focusing on both internal growth and external expansion [4].

Core Viewpoint - Yibai Pharmaceutical has faced significant financial challenges due to the suspension of its exclusive product, Aidi Injection, leading to a substantial decline in revenue and a net loss in 2024 [2][7]. Financial Performance - In 2024, Yibai Pharmaceutical reported total revenue of 2.174 billion, a decrease of 22.92% compared to the previous year [3][7]. - The net profit attributable to shareholders was a loss of 317.22 million, marking a 406.79% decline year-on-year [3][7]. - The net cash flow from operating activities fell by 76.99% to 86.87 million [3]. - The pharmaceutical industrial segment's revenue dropped by 28.36% to 1.684 billion, primarily due to the impact of the suspension of Aidi Injection [7]. Product and Market Impact - Aidi Injection, a key product for Yibai Pharmaceutical, has seen a decline in revenue over recent years, with sales dropping from 7.37 billion in 2020 to 4.73 billion in 2023 [12]. - The suspension of Aidi Injection has led to the loss of its selected status in centralized procurement, resulting in an estimated revenue loss of approximately 499 million from 2020 to 2023 [6]. Recovery Efforts - Yibai Pharmaceutical has completed internal rectification related to the production issues and is in discussions with regulatory authorities to resume production of Aidi Injection [2][6]. - The company reported a slight recovery in the first quarter of 2025, with revenue of 501 million, a decrease of 12.43% year-on-year, and a reduced net loss compared to the previous year [8]. R&D and Future Strategy - Despite financial pressures, Yibai Pharmaceutical has maintained its commitment to R&D, with a reported R&D expenditure of 100.5 million in 2024, although this represents a 10.38% decrease from the previous year [12][14]. - The company is focusing on diversifying its product line and enhancing its R&D capabilities to reduce reliance on single products [14].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing growth driven by its anesthesia business, innovation, and international expansion. The revenue for 2024 is projected to be 1.35 billion yuan, representing a year-on-year increase of 20.82%. The net profit attributable to the parent company is expected to be 238 million yuan, up 5.15% year-on-year [4][5] - The company has received approval for 13 high-end formulation products in 2024, contributing to revenue growth. The overseas business is expected to grow rapidly, with the approval of the hydrochloride injection of Nicardipine by the FDA [5][6] Financial Summary - The company's revenue for 2024 is projected at 1.35 billion yuan, with a year-on-year growth of 20.82%. The net profit attributable to the parent company is expected to be 238 million yuan, reflecting a 5.15% increase year-on-year. The earnings per share (EPS) for 2025 is estimated to be 1.53 yuan, with a price-to-earnings (P/E) ratio of 22.3 times [4][8] - The company’s gross margin is projected to be 74.9% in 2024, with a net margin of 17.7%. The return on equity (ROE) is expected to be 8.8% [8][11]

Core Viewpoint - The report highlights that Yuandong Biopharmaceutical has received approval for new products, which are expected to drive growth through internationalization and innovation, maintaining a "buy" rating for the company [1] Financial Performance - In 2024, the company achieved revenue of 1.35 billion yuan (+20.82% year-on-year), with a net profit attributable to shareholders of 238 million yuan (+5.15%) and a net profit excluding non-recurring items of 175 million yuan (+10.90%). After excluding stock incentive expenses, the net profit increased by 13.47% year-on-year, and the net profit excluding non-recurring items rose by 22.87% [1] - For Q1 2025, the company reported revenue of 306 million yuan (-2.97%) and a net profit attributable to shareholders of 61 million yuan (-19.22%), with a net profit excluding non-recurring items of 46 million yuan (-10.79%). The profit in Q1 2025 was under pressure due to stock incentive expenses [1] Business Segments Growth - The chemical preparations segment generated revenue of 1.077 billion yuan (+22.25%), the raw materials segment 121 million yuan (+28.65%), and the CMO/CDMO business 65 million yuan (+111.59%). However, technical services and transfers saw a decline in revenue of 63 million yuan (-42.81%) [2] - Domestic revenue reached 1.324 billion yuan (+20.04%), while overseas revenue was 25 million yuan (+84.66%). The growth in the chemical preparations segment was driven by both existing and newly approved products, with 13 high-end preparation products approved in 2024 [2] R&D and Innovation - The company invested approximately 290 million yuan in R&D in 2024, accounting for 21.31% of revenue, with 83 million yuan allocated to new drug development [3] - The company has a rich pipeline of products under development, including a diabetes drug that has reached Phase III clinical trials and several other innovative drugs that have received clinical trial approvals [3] Profit Forecast and Investment Rating - The profit forecast for 2025-2026 has been adjusted to 281 million yuan and 335 million yuan, respectively, with an expected profit of 401 million yuan in 2027. The corresponding PE ratios are 21, 18, and 15 times, indicating strong growth potential as new products are approved [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has received approval for new products, which are expected to gradually increase in volume, driving growth through internationalization and innovation [1] - In 2024, the company achieved a total revenue of 1.35 billion yuan, representing a year-on-year increase of 20.82%, and a net profit attributable to shareholders of 238.23 million yuan, up 5.15% year-on-year [7] - The company is focusing on the anesthesia and analgesia sector, with significant investments in research and development, which accounted for 21.31% of revenue in 2024 [7] Financial Performance Summary - Total revenue projections for the company are as follows: 1.35 billion yuan in 2024, 1.59 billion yuan in 2025, 1.90 billion yuan in 2026, and 2.26 billion yuan in 2027, with respective year-on-year growth rates of 20.82%, 18.02%, 18.98%, and 19.31% [1][8] - The net profit attributable to shareholders is projected to be 238.23 million yuan in 2024, 281.30 million yuan in 2025, 335.30 million yuan in 2026, and 400.75 million yuan in 2027, with year-on-year growth rates of 5.15%, 18.08%, 19.20%, and 19.52% respectively [1][8] - The company’s earnings per share (EPS) are expected to be 1.35 yuan in 2024, 1.59 yuan in 2025, 1.90 yuan in 2026, and 2.27 yuan in 2027 [1][8] Business Segment Performance - The chemical formulation segment generated revenue of 1.077 billion yuan in 2024, up 22.25% year-on-year, while the raw materials segment saw revenue of 121 million yuan, an increase of 28.65% [7] - The CMO/CDMO business experienced significant growth, with revenue reaching 65 million yuan, a remarkable increase of 111.59% [7] - The company has successfully launched 16 anesthesia and analgesia products and has over 20 products in development, indicating a strong competitive position in the market [7]

分产品来看，去年，手工具业务收入为100.69亿元，同比增长40.46%；电动工具业务收入为14.38亿 元，同比增长36.53%；工业工具业务收入为32.28亿元，同比增长22.14%。 手工具方面，去年巨星科技以品牌和产品驱动业务发展，跨境电商业务保持45%以上的增速。继续拓展 全球经销商网络，助力非美地区尤其是共建"一带一路"自有品牌的发展，自有品牌的迅猛发展带动公司 盈利能力继续提升。另外，公司针对市场需求开发了针对非美地区的全新系列产品，完善现有产品系 列，取得客户新订单；东南亚产能的投放提升了公司的产能天花板，帮助公司更好满足客户的订单需 求。 年报显示，经过近10年的努力，巨星科技已经建立了行业内完善的全球化生产和供应链管理体系，与全 球数千家供应商建立了良好的合作关系，确保公司不局限于任何单一国家和自身产能。 4月21日晚，巨星科技（002444）发布2024年年报。公司去年实现营业收入147.95亿元，同比增长 35.37%；实现归母净利润23.04亿元，同比增长36.18%，扣非净利润23.04亿元,同比增长35.74%。 总部位于浙江杭州的巨星科技，主要产品包括手工具、电动工具及工业工具 ...